{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:13:26Z","timestamp":1773281606333,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant in resistant diabetic macular edema that have different morphological types.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this retrospective study, 31 patients (35 eyes) with persistent diabetic macular edema, who underwent a single injection of dexamethasone implant, were evaluated. Diabetic macular edema was classified into three types: diffuse retinal thickening (n = 10), cystoid macular edema (n = 13), and serous retinal detachment (n = 12). Primary outcome measures were best corrected visual acuity, and central macular thickness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The three subgroups were similar in terms of age and gender (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). Total duration of diabetes was significantly less in the serous retinal detachment subgroup (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01). There were no differences in the best corrected visual acuity between the three subgroups until the sixth month. However, the best corrected visual acuity was significantly better in the diffuse retinal thickness subgroup at the sixth month (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008). Regarding the central macular thickness values, it was statistically better in serous retinal detachment than in diffuse retinal thickening and cystoid macular edema subgroups till the sixth month (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001). However, at the sixth month, there was not any statistical difference between subgroups regarding central macular thickness values. Antiglaucomatous agents were required in 4 (11.4%) patients throughout the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Treatment algorithms should differ according to the morphology of diabetic macular edema; however, more data is needed to give specific recommendations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001648","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T14:17:17Z","timestamp":1492697837000},"page":"986-992","source":"Crossref","is-referenced-by-count":17,"title":["INTRAVITREAL DEXAMETHASONE IMPLANTATION IN PATIENTS WITH DIFFERENT MORPHOLOGICAL DIABETIC MACULAR EDEMA HAVING INSUFFICIENT RESPONSE TO RANIBIZUMAB"],"prefix":"10.1097","volume":"38","author":[{"given":"Havva","family":"Kald\u0131r\u0131m","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Bagcilar Education and Research Hospital, Istanbul, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serpil","family":"Yazgan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bulent Ecevit University, Zonguldak, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kursat","family":"Atalay","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bagcilar Education and Research Hospital, Istanbul, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceren","family":"Gurez","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bagcilar Education and Research Hospital, Istanbul, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Savur","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bagcilar Education and Research Hospital, Istanbul, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of vitreous inflammatory factors with diabetic macular edema","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(99)00033-1","article-title":"Patterns of diabetic macular edema with optical coherence tomography","volume":"127","author":"Otani","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","article-title":"Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema","volume":"33","author":"Shimura","year":"2013","journal-title":"Retina"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/IAE.0000000000000770","article-title":"Visual and morphologic outcomes of intravitreal ranibizumab for d\u0131abet\u0131c macular edema based on opt\u0131cal coherence tomography patterns","volume":"36","author":"Seo","year":"2016","journal-title":"Retina"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/jop.2011.0070","article-title":"Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment","volume":"28","author":"Wu","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2012.07.058","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"119","author":"Ho","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20230816","first-page":"CD005656","article-title":"Intravitreal steroids for macular edema in diabetes","volume":"1","author":"Grover","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S48364","article-title":"Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema","volume":"7","author":"Pacella","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R9-20230816","first-page":"CD007419","article-title":"Antivascular endothelial growth factor for diabetic macular edema","volume":"10","author":"Virgili","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/02713683.2014.1002048","article-title":"Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment","volume":"41","author":"Totan","year":"2016","journal-title":"Curr Eye Res"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/IAE.0b013e3182a48958","article-title":"Treatment of antivascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant","volume":"34","author":"Lazic","year":"2014","journal-title":"Retina"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000356413","article-title":"Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema","volume":"231","author":"Dutra Medeiros","year":"2014","journal-title":"Ophthalmologica"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-620X.99368","article-title":"Short-term results of intravitreal dexamethasone implant (OZURDEX) in treatment of recalcitrant diabetic macular edema: a case series","volume":"5","author":"Rishi","year":"2012","journal-title":"Oman J Ophthalmol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000336225","article-title":"Intravitreal dexamethasone implant in patients with persistent diabetic macular edema","volume":"228","author":"Zucchiatti","year":"2012","journal-title":"Ophthalmologica"},{"key":"R15-20230816","first-page":"41","article-title":"Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant","volume":"36","author":"Zalewski","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10792-016-0219-2","article-title":"Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema","volume":"37","author":"Esen","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1167\/iovs.04-0905","article-title":"Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina","volume":"46","author":"Tamura","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1248\/bpb.31.1541","article-title":"Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression","volume":"31","author":"Wang","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-015-0148-2","article-title":"Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study","volume":"15","author":"Augustin","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/0301-4738.158069","article-title":"Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema","volume":"63","author":"Kim","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjo.2008.152553","article-title":"Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation","volume":"93","author":"Kim","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.eye.6702408","article-title":"Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection","volume":"21","author":"Shulman","year":"2007","journal-title":"Eye"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000330045","article-title":"Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ajo.2007.12.031","article-title":"Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema","volume":"145","author":"Shimura","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/IAE.0000000000000443","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema","volume":"35","author":"Scaramuzzi","year":"2015","journal-title":"Retina"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5301\/ejo.5000563","article-title":"Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment","volume":"25","author":"Panozzo","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/eye.2013.287","article-title":"Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1)","volume":"28","author":"Mathew","year":"2014","journal-title":"Eye (Lond)"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201805000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:14:12Z","timestamp":1692231252000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201805000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001648","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}